Showing results (181-190 of 255) with videos related to
Sort By:
Pageof 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016Oliver W Press, Joseph M Unger, Lisa M Rimsza, et al.Blood|December 8, 2009
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemiaJonathan W Friedberg, Jeff Sharman, John Sweetenham, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2015
Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108Paul M Barr, Hongli Li, Catherine Spier, et al.Journal of the National Comprehensive Cancer Network : JNCCN|October 5, 2016
High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male SexZheng Zhou, Alfred W Rademaker, Leo I Gordon, et al.JAMA Network Open|January 19, 2024
Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in ChildrenAndrea C Lo, Amy Liu, Qi Liu, et al.Blood|July 28, 2018
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PETDavid J Straus, Sin-Ho Jung, Brandelyn Pitcher, et al.Blood Advances|April 10, 2024
Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101Tracy T Batchelor, Sharmila Giri, Amy S Ruppert, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2019
Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin LymphomaRadhakrishnan Ramchandren, Ranjana H Advani, Stephen M Ansell, et al.Hematological Oncology|January 19, 2021
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 studyMartin Hutchings, John Radford, Stephen M Ansell, et al.British Journal of Haematology|June 13, 2009
Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphomaJonathan W Friedberg, Jennifer L Kelly, Donna Neuberg, et al.Pageof 26